Indeed, T cells must traverse the tumor vasculature (52), and survive tumor-derived inhibitory factors such as TGF-β and IL-10 which can inhibit antigen presentation, T cell activation, and expand of CD3+CD4+FoxP3+ regulatory T cells (55–57),, which have recently been implicated in the direct suppression of γδ T cell function (58). The gene discussed is TGFB1; the disease is neoplasm.